iFANN
    ค้นหาใน iFANN...
    เข้าสู่ระบบ
    หน้าแรก
    ข่าว
    วิดีโอ
    รูปภาพ
    GIF
    สำรวจ
    โพล
    รางวัล
    iFAMOUS
    วิกิ
    อนิเมะ
    ห้อง
    การแจ้งเตือน
    ข้อความ
    ที่บันทึกไว้
    โปรไฟล์
    วิกิรางวัลiFAMOUSอันดับอุตสาหกรรมรางวัลครีเอเตอร์รางวัลผู้ใช้ข้อกำหนดความเป็นส่วนตัวหลักเกณฑ์ชุมชนแจ้งลบ / DMCAช่วยเหลือนักพัฒนา

    © 2026 iFANN

    หน้าแรก
    ค้นหา
    ข้อความ
    การแจ้งเตือน
    โปรไฟล์

    โพสต์

    Gloriaunhinged
    Gloriaunhinged@gloriaunhinged
    💭Health💭Science

    CARv3-TEAM-E glioblastoma trial MRI results

    What showed up on the scans five days after one infusion is the part doctors are still calling jaw-dropping. Three people with recurrent glioblastoma came to Massachusetts General Hospital in early 2024, and the therapy they got, CARv3-TEAM-E, is a CAR T-cell approach that starts with each patient's own immune cells. Those cells get genetically rewired in the lab so they recognize two markers that tend to sit on glioblastoma cells. Then they go straight into the fluid spaces of the brain, and it all happens through one procedure. From there the outcomes split in ways nobody was ready for. One patient's MRI at day five showed the tumor had nearly vanished. Another patient's tumor shrank by more than 60 percent, and that reduction held for over six months. The third patient had clear tumor reduction within days. Compare that with what immunotherapy had done for this type of brain cancer before, and the speed and the size of the response are on another level entirely. The early images being described as jaw-dropping feels less like hype and more like an understatement.

    1mo

    521 ถูกใจ31 ไม่ถูกใจ84 รีโพสต์24 ความคิดเห็น
    ?

    ความคิดเห็น

    ยังไม่มีความคิดเห็น มาเป็นคนแรกกันเถอะ!

    โพสต์

    Gloriaunhinged
    Gloriaunhinged@gloriaunhinged
    💭Health💭Science

    CARv3-TEAM-E glioblastoma trial MRI results

    What showed up on the scans five days after one infusion is the part doctors are still calling jaw-dropping. Three people with recurrent glioblastoma came to Massachusetts General Hospital in early 2024, and the therapy they got, CARv3-TEAM-E, is a CAR T-cell approach that starts with each patient's own immune cells. Those cells get genetically rewired in the lab so they recognize two markers that tend to sit on glioblastoma cells. Then they go straight into the fluid spaces of the brain, and it all happens through one procedure. From there the outcomes split in ways nobody was ready for. One patient's MRI at day five showed the tumor had nearly vanished. Another patient's tumor shrank by more than 60 percent, and that reduction held for over six months. The third patient had clear tumor reduction within days. Compare that with what immunotherapy had done for this type of brain cancer before, and the speed and the size of the response are on another level entirely. The early images being described as jaw-dropping feels less like hype and more like an understatement.

    1mo

    521 ถูกใจ31 ไม่ถูกใจ84 รีโพสต์24 ความคิดเห็น
    ?

    ความคิดเห็น

    ยังไม่มีความคิดเห็น มาเป็นคนแรกกันเถอะ!